Net Prescription Drug Prices And Spending In Medicare Part D Before And After Generic Entry
Health Affairs · 2026
DOI: 10.1377/hlthaff.2026.00257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, 2026. Verfasst von Scott Laughery und 2 weiteren Autor:innen. Beteiligte Einrichtung: Scott Laughery, Congressional Budget Office, Washington, D.C. Hauptthemen laut MEDLINE: Drugs, Generic, Medicare Part D, Drug Costs, Prescription Drugs. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Generic competition lowers retail prescription drug prices, but little is known about its effect on net prices, accounting for manufacturer rebates. Using data on rebates and discounts for Part D, we estimated net prices, prescription volume, and spending before and after generic entry. Total spending fell as generics captured market share, even as total volume rose. Brand-name prices rose in a shrinking segment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Scott Laughery, Congressional Budget Office, Washington, D.C.
- Colin Baker (colin.baker@cbo.gov), Congressional Budget Office.
- Rachel Fehr, formerly Congressional Budget Office.
Zitieren
APA
Laughery, S., Baker, C., & Fehr, R. (2026). Net Prescription Drug Prices And Spending In Medicare Part D Before And After Generic Entry. Health Affairs. https://doi.org/10.1377/hlthaff.2026.00257
Vancouver
Laughery S, Baker C, Fehr R. Net Prescription Drug Prices And Spending In Medicare Part D Before And After Generic Entry. Health Affairs. 2026. doi:10.1377/hlthaff.2026.00257
BibTeX
@article{Laughery2026,
author = {Laughery, Scott and Baker, Colin and Fehr, Rachel},
title = {Net Prescription Drug Prices And Spending In Medicare Part D Before And After Generic Entry},
journal = {Health Affairs},
year = {2026},
doi = {10.1377/hlthaff.2026.00257}
}
EUVIMED